Denali Therapeutics Income Statement (2017-2026) | DNLI

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Jun2026
Shares Outstanding (Entity) (Quarter)
159.76M
Revenue & cost
Revenue (Quarter)
4.10M13.51M4.67M0.05M5.81M9.39M316.81M7.92M15.00M5.29M48.65M42.14M52.48M3.38M10.00M35.14M294.12M1.27M3.60M
Gross Profit (Quarter)
3.51M
Operating items
Research & Development (Quarter)
97.02M
Selling, General & Administrative (Quarter)
36.28M
Amortization - Intangibles (Quarter)
0.75M
Other Operating Expenses (Quarter)
0.84M
Operating Expenses (Quarter)
134.15M
Operating Income (Quarter)
-130.54M
EBIT (Quarter)
-130.54M
Non-operating items
Interest & Investment Income (Quarter)
2.99M
Non Operating Income (Quarter)
4.11M11.41M3.07M2.60M1.94M1.63M1.18M1.13M1.00M1.28M1.28M2.65M4.19M6.66M11.03M12.90M14.44M13.13M
Net income details
EBT (Quarter)
-130.55M
Tax Provisions (Quarter)
-0.31M-0.40M-0.10M0.08M0.06M0.82M-0.57M0.03M-0.01M0.03M
Profit After Tax (Quarter)
-128.84M
Income from Continuing Operations (Quarter)
-130.55M
Consolidated Net Income (Quarter)
-130.55M
Income towards Parent Company (Quarter)
-130.55M
Net Income towards Common Stockholders (Quarter)
-130.55M
Additional items
EPS (Basic) (Quarter)
-0.70
EPS (Diluted) (Quarter)
-0.70
Shares Outstanding (Quarter)
187.31M
Shares Outstanding (Diluted) (Quarter)
187.31M
EBITDA (Quarter)
-130.54M
Interest Expenses (Quarter)
3.00M
Tax Rate (Quarter)
0.530.280.18-0.13-0.100.330.76-0.050.01-0.03